2026 Q2 - tulosraportti
82 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,50%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 | - | - | ||
| 1 | - | - | ||
| 18 | - | - | ||
| 218 | - | - | ||
| 324 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·6 t sittenNovo Nordisk strengthens its collaboration with leading universities - Duke, Oxford and Barcelona - and announces a new research collaboration on glucagon. Novo Nordisk has in recent weeks announced several new collaborations with universities and research institutions within, among other things, obesity, diabetes, artificial intelligence and the development of new medicines. The most important news 1. Duke University, USA - new research in glucagon On October 25, Duke University announced a new research collaboration with Novo Nordisk. The project is led by Professor Sudha Shenoy and will investigate Novo Nordisk's glucagon analogues. The researchers will study the function of the glucagon receptor and the body's physiological reactions relevant to obesity, diabetes, and cardiovascular and metabolic diseases. This is interesting because Novo Nordisk is working on the next generation of obesity treatments that affect multiple hormone receptors - including the glucagon receptor. 2. University of Barcelona, Spain - a more holistic obesity treatment Novo Nordisk and the university have established a new academic professorship focusing on a more holistic approach to obesity treatment. The initiative is supported by the Hospital Clínic de Barcelona and includes education, healthcare and knowledge sharing. 3. Oxford University, UK - collaboration on AI and digital innovation Oxford has appointed Dr. Mishal Patel, Novo Nordisk's Global Vice President for AI and Digital Innovation, as visiting professor. The purpose is to strengthen the university's existing scientific collaboration with Novo Nordisk, especially within artificial intelligence and computer science. 4. Unicamp, Brazil - clinical research in heart disease On September 8, Unicamp approved a clinical research agreement where Novo Nordisk A/S is the sponsor of the CLEOPATTRA study. The study investigates the drug candidate NNC6019-0001 against transthyretin amyloid cardiomyopathy, a serious heart disease where abnormal protein deposits affect the heart. This collaboration is particularly relevant because it concerns Novo Nordisk's clinical drug development. 5. The Novo Nordisk Foundation and Broad Institute - 53 million dollars for research On September 30, the Novo Nordisk Foundation announced an additional 53 million dollars for the Broad Institute at MIT and Harvard. The funds will support research into the biological and genetic mechanisms behind obesity and type 2 diabetes. Global research network Novo Nordisk's academic collaborations reach far beyond Europe and the USA. According to the text, the network also includes universities in, among others: Asia: China, Japan and Malaysia. South America: Brazil, Chile, Argentina and Colombia. Europe: Sweden and several other countries. The collaborations cover drug research, clinical trials, metabolic diseases, drug development, medical education and public health. What does this mean strategically for Novo Nordisk? The new collaborations point to three central strategic focus areas: Next generation of obesity treatments: Research in glucagon can contribute to the development of treatments that affect multiple hormonal mechanisms. Expansion of the research foundation: Collaborations with leading universities can provide access to specialized expertise, research environments and new technologies. Broader research portfolio: The focus is not only on obesity and diabetes, but also on cardiovascular diseases, genetics and AI.
·9 t sittenI have summarized the week's most important Novo news in this post: https://x.com/investseekers/status/2114395236403233059?s=20
·10 t sittenDSV and Novo - The battle of two lighthouses with the share price https://proinvestor.com/forum/topic/560136/dsv-og-novo-to-fyrt%C3%A5rnes-kamp-med-aktiekursen
·17 t sittenYes, it's not like things have really moved forward for the company since they ousted Lars Jørgensen😂 Even though he spoke dænglish, he probably knew something they are now unable to do.He made several mistakes which he has also been rebuked for, where the most critical was the lacking production capacity for a revolutionary drug. It seems like the most obvious thing that one must be able to manufacture and distribute sufficiently when one is a first mover on such a product,
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
82 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,50%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·6 t sittenNovo Nordisk strengthens its collaboration with leading universities - Duke, Oxford and Barcelona - and announces a new research collaboration on glucagon. Novo Nordisk has in recent weeks announced several new collaborations with universities and research institutions within, among other things, obesity, diabetes, artificial intelligence and the development of new medicines. The most important news 1. Duke University, USA - new research in glucagon On October 25, Duke University announced a new research collaboration with Novo Nordisk. The project is led by Professor Sudha Shenoy and will investigate Novo Nordisk's glucagon analogues. The researchers will study the function of the glucagon receptor and the body's physiological reactions relevant to obesity, diabetes, and cardiovascular and metabolic diseases. This is interesting because Novo Nordisk is working on the next generation of obesity treatments that affect multiple hormone receptors - including the glucagon receptor. 2. University of Barcelona, Spain - a more holistic obesity treatment Novo Nordisk and the university have established a new academic professorship focusing on a more holistic approach to obesity treatment. The initiative is supported by the Hospital Clínic de Barcelona and includes education, healthcare and knowledge sharing. 3. Oxford University, UK - collaboration on AI and digital innovation Oxford has appointed Dr. Mishal Patel, Novo Nordisk's Global Vice President for AI and Digital Innovation, as visiting professor. The purpose is to strengthen the university's existing scientific collaboration with Novo Nordisk, especially within artificial intelligence and computer science. 4. Unicamp, Brazil - clinical research in heart disease On September 8, Unicamp approved a clinical research agreement where Novo Nordisk A/S is the sponsor of the CLEOPATTRA study. The study investigates the drug candidate NNC6019-0001 against transthyretin amyloid cardiomyopathy, a serious heart disease where abnormal protein deposits affect the heart. This collaboration is particularly relevant because it concerns Novo Nordisk's clinical drug development. 5. The Novo Nordisk Foundation and Broad Institute - 53 million dollars for research On September 30, the Novo Nordisk Foundation announced an additional 53 million dollars for the Broad Institute at MIT and Harvard. The funds will support research into the biological and genetic mechanisms behind obesity and type 2 diabetes. Global research network Novo Nordisk's academic collaborations reach far beyond Europe and the USA. According to the text, the network also includes universities in, among others: Asia: China, Japan and Malaysia. South America: Brazil, Chile, Argentina and Colombia. Europe: Sweden and several other countries. The collaborations cover drug research, clinical trials, metabolic diseases, drug development, medical education and public health. What does this mean strategically for Novo Nordisk? The new collaborations point to three central strategic focus areas: Next generation of obesity treatments: Research in glucagon can contribute to the development of treatments that affect multiple hormonal mechanisms. Expansion of the research foundation: Collaborations with leading universities can provide access to specialized expertise, research environments and new technologies. Broader research portfolio: The focus is not only on obesity and diabetes, but also on cardiovascular diseases, genetics and AI.
- ·9 t sittenI have summarized the week's most important Novo news in this post: https://x.com/investseekers/status/2114395236403233059?s=20
- ·10 t sittenDSV and Novo - The battle of two lighthouses with the share price https://proinvestor.com/forum/topic/560136/dsv-og-novo-to-fyrt%C3%A5rnes-kamp-med-aktiekursen
- ·17 t sittenYes, it's not like things have really moved forward for the company since they ousted Lars Jørgensen😂 Even though he spoke dænglish, he probably knew something they are now unable to do.He made several mistakes which he has also been rebuked for, where the most critical was the lacking production capacity for a revolutionary drug. It seems like the most obvious thing that one must be able to manufacture and distribute sufficiently when one is a first mover on such a product,
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 | - | - | ||
| 1 | - | - | ||
| 18 | - | - | ||
| 218 | - | - | ||
| 324 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
82 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,50%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·6 t sittenNovo Nordisk strengthens its collaboration with leading universities - Duke, Oxford and Barcelona - and announces a new research collaboration on glucagon. Novo Nordisk has in recent weeks announced several new collaborations with universities and research institutions within, among other things, obesity, diabetes, artificial intelligence and the development of new medicines. The most important news 1. Duke University, USA - new research in glucagon On October 25, Duke University announced a new research collaboration with Novo Nordisk. The project is led by Professor Sudha Shenoy and will investigate Novo Nordisk's glucagon analogues. The researchers will study the function of the glucagon receptor and the body's physiological reactions relevant to obesity, diabetes, and cardiovascular and metabolic diseases. This is interesting because Novo Nordisk is working on the next generation of obesity treatments that affect multiple hormone receptors - including the glucagon receptor. 2. University of Barcelona, Spain - a more holistic obesity treatment Novo Nordisk and the university have established a new academic professorship focusing on a more holistic approach to obesity treatment. The initiative is supported by the Hospital Clínic de Barcelona and includes education, healthcare and knowledge sharing. 3. Oxford University, UK - collaboration on AI and digital innovation Oxford has appointed Dr. Mishal Patel, Novo Nordisk's Global Vice President for AI and Digital Innovation, as visiting professor. The purpose is to strengthen the university's existing scientific collaboration with Novo Nordisk, especially within artificial intelligence and computer science. 4. Unicamp, Brazil - clinical research in heart disease On September 8, Unicamp approved a clinical research agreement where Novo Nordisk A/S is the sponsor of the CLEOPATTRA study. The study investigates the drug candidate NNC6019-0001 against transthyretin amyloid cardiomyopathy, a serious heart disease where abnormal protein deposits affect the heart. This collaboration is particularly relevant because it concerns Novo Nordisk's clinical drug development. 5. The Novo Nordisk Foundation and Broad Institute - 53 million dollars for research On September 30, the Novo Nordisk Foundation announced an additional 53 million dollars for the Broad Institute at MIT and Harvard. The funds will support research into the biological and genetic mechanisms behind obesity and type 2 diabetes. Global research network Novo Nordisk's academic collaborations reach far beyond Europe and the USA. According to the text, the network also includes universities in, among others: Asia: China, Japan and Malaysia. South America: Brazil, Chile, Argentina and Colombia. Europe: Sweden and several other countries. The collaborations cover drug research, clinical trials, metabolic diseases, drug development, medical education and public health. What does this mean strategically for Novo Nordisk? The new collaborations point to three central strategic focus areas: Next generation of obesity treatments: Research in glucagon can contribute to the development of treatments that affect multiple hormonal mechanisms. Expansion of the research foundation: Collaborations with leading universities can provide access to specialized expertise, research environments and new technologies. Broader research portfolio: The focus is not only on obesity and diabetes, but also on cardiovascular diseases, genetics and AI.
- ·9 t sittenI have summarized the week's most important Novo news in this post: https://x.com/investseekers/status/2114395236403233059?s=20
- ·10 t sittenDSV and Novo - The battle of two lighthouses with the share price https://proinvestor.com/forum/topic/560136/dsv-og-novo-to-fyrt%C3%A5rnes-kamp-med-aktiekursen
- ·17 t sittenYes, it's not like things have really moved forward for the company since they ousted Lars Jørgensen😂 Even though he spoke dænglish, he probably knew something they are now unable to do.He made several mistakes which he has also been rebuked for, where the most critical was the lacking production capacity for a revolutionary drug. It seems like the most obvious thing that one must be able to manufacture and distribute sufficiently when one is a first mover on such a product,
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 | - | - | ||
| 1 | - | - | ||
| 18 | - | - | ||
| 218 | - | - | ||
| 324 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt